25,147 Shares in Eli Lilly and Company $LLY Purchased by MASTERINVEST Kapitalanlage GmbH

MASTERINVEST Kapitalanlage GmbH acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the second quarter, Holdings Channel reports. The firm acquired 25,147 shares of the company’s stock, valued at approximately $19,603,000. Eli Lilly and Company makes up approximately 2.1% of MASTERINVEST Kapitalanlage GmbH’s investment portfolio, making the stock its 9th largest holding.

A number of other hedge funds have also added to or reduced their stakes in LLY. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new position in Eli Lilly and Company during the 2nd quarter worth $27,000. Financial Gravity Companies Inc. bought a new stake in Eli Lilly and Company during the 2nd quarter valued at $31,000. Bare Financial Services Inc raised its position in Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 29 shares in the last quarter. Finally, Blume Capital Management Inc. lifted its holdings in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 1.8%

NYSE LLY opened at $1,027.68 on Monday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99. The company has a 50 day moving average price of $939.47 and a 200 day moving average price of $820.35. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The firm has a market cap of $971.55 billion, a PE ratio of 50.28, a price-to-earnings-growth ratio of 1.14 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on LLY shares. BMO Capital Markets set a $1,200.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, December 4th. Guggenheim reaffirmed a “buy” rating and issued a $1,163.00 price target on shares of Eli Lilly and Company in a research report on Wednesday, December 3rd. Berenberg Bank increased their price objective on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research note on Tuesday, December 2nd. Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $886.00 to $1,104.00 in a research note on Monday, November 10th. Finally, Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,121.90.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.